ReproCell

ReproCell Goodwill

Poslovni ugled od ReproCell (4978.T) na dan 30. okt. 2026 je 5,43 Mio. JPY. V prejšnjem letu je Poslovni ugled znašal 8,14 Mio. JPY — sprememba za −33,33 % (nižje).

Goodwill

5,43 Mio.JPY

YoY

−33,33%

Zadnja posodobitev:

Poslovni ugled od ReproCell je 2026 5,43 Mio. JPY. Poslovni ugled od ReproCell je bil 2025 8,14 Mio. JPY. Pada za −33,33% nižje v primerjavi s prejšnjim letom.

Zgodovina ReproCell Goodwill

  • 3 leta

  • 10 let

  • 25 let

  • Največ

Goodwill
Datum
Goodwill
1. jan. 2019
107,03 Mio. JPY
1. jan. 2020
21,70 Mio. JPY
1. jan. 2021
18,99 Mio. JPY
1. jan. 2022
16,28 Mio. JPY
1. jan. 2023
13,57 Mio. JPY
1. jan. 2024
10,85 Mio. JPY
1. jan. 2025
8,14 Mio. JPY
1. jan. 2026
5,43 Mio. JPY
Zgodovina ReproCell Goodwill
LETOGoodwillYoY
5,43 Mio.JPY−33,33%
8,14 Mio.JPY−25,00%
10,85 Mio.JPY−20,00%
13,57 Mio.JPY−16,67%
16,28 Mio.JPY−14,29%
18,99 Mio.JPY−12,50%
21,70 Mio.JPY−79,72%
107,03 Mio.JPY−89,88%
1,06 Mrd.JPY−21,37%
1,35 Mrd.JPY−0,49%
1,35 Mrd.JPY—

Do teh podatkov prek Eulerpool API

100.000 zahtevkov/mes. brezplačno · brez kartice

ReproCell Analiza delnic

Kaj dela ReproCell? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell je eno najbolj priljubljenih podjetij na Eulopoolu.

Pogosto zastavljena vprašanja o delnici ReproCell

Poslovni ugled podjetja ReproCell znaša 5,43 Mio. JPY v letu 2026.

Poslovni ugled od ReproCell se je spremenil z 8,14 Mio. JPY na 5,43 Mio. JPY, kar predstavlja spremembo za −33,33 %. Vrednost je nižje kot v prejšnjem letu.

Na Eulopoolu najdete celovit zgodovinski razvoj Poslovni ugled ReproCell od leta 2006 – z letnimi vrednostmi, grafi in podrobno analizo.

Poslovni ugled je premija, ki se plača nad pošteno tržno vrednostjo pri prevzemu. Predstavlja neopredmeteno vrednost, kot so prepoznavnost blagovne znamke, odnosov s strankami in intelektualno lastnino.

Poslovni ugleds JPY je ključni dejavnik za vlagatelje. Spremembe te metrike lahko signalizirajo izboljšanje ali poslabšanje temeljnih podatkov, kar neposredno vpliva na ceno delnice. Na Euloolu lahko spremljate Poslovni ugleds ReproCell v realnem času in zgodovinsko.

Do teh podatkov prek Eulerpool API

100.000 zahtevkov/mes. brezplačno · brez kartice

Bilanca stanja — ReproCell

Vse ključne metrike — ReproCell